210 related articles for article (PubMed ID: 38094080)
1. Harnessing IGF-1 and IL-2 as biomarkers for calcineurin activity to tailor optimal FK506 dosage in α-synucleinopathies.
Zaichick S; Caraveo G
Front Mol Biosci; 2023; 10():1292555. PubMed ID: 38094080
[No Abstract] [Full Text] [Related]
2. FKBP12 contributes to α-synuclein toxicity by regulating the calcineurin-dependent phosphoproteome.
Caraveo G; Soste M; Cappelleti V; Fanning S; van Rossum DB; Whitesell L; Huang Y; Chung CY; Baru V; Zaichick S; Picotti P; Lindquist S
Proc Natl Acad Sci U S A; 2017 Dec; 114(52):E11313-E11322. PubMed ID: 29229832
[TBL] [Abstract][Full Text] [Related]
3. Differential calcium alterations in animal models of neurodegenerative disease: Reversal by FK506.
Overk CR; Rockenstein E; Florio J; Cheng Q; Masliah E
Neuroscience; 2015 Dec; 310():549-60. PubMed ID: 26341908
[TBL] [Abstract][Full Text] [Related]
4. Calcineurin determines toxic versus beneficial responses to α-synuclein.
Caraveo G; Auluck PK; Whitesell L; Chung CY; Baru V; Mosharov EV; Yan X; Ben-Johny M; Soste M; Picotti P; Kim H; Caldwell KA; Caldwell GA; Sulzer D; Yue DT; Lindquist S
Proc Natl Acad Sci U S A; 2014 Aug; 111(34):E3544-52. PubMed ID: 25122673
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology.
Gerard M; Deleersnijder A; Daniëls V; Schreurs S; Munck S; Reumers V; Pottel H; Engelborghs Y; Van den Haute C; Taymans JM; Debyser Z; Baekelandt V
J Neurosci; 2010 Feb; 30(7):2454-63. PubMed ID: 20164329
[TBL] [Abstract][Full Text] [Related]
6. Effects of cyclosporin A and FK506 on Fc epsilon receptor type I-initiated increases in cytokine mRNA in mouse bone marrow-derived progenitor mast cells: resistance to FK506 is associated with a deficiency in FK506-binding protein FKBP12.
Kaye RE; Fruman DA; Bierer BE; Albers MW; Zydowsky LD; Ho SI; Jin YJ; Castells MC; Schreiber SL; Walsh CT
Proc Natl Acad Sci U S A; 1992 Sep; 89(18):8542-6. PubMed ID: 1382293
[TBL] [Abstract][Full Text] [Related]
7. Ca
Ueda J; Uemura N; Ishimoto T; Taguchi T; Sawamura M; Nakanishi E; Ikuno M; Matsuzawa S; Yamakado H; Takahashi R
Mov Disord; 2023 Jun; 38(6):1056-1067. PubMed ID: 37066491
[TBL] [Abstract][Full Text] [Related]
8. Proteasomal degradation of IRS-2, but not IRS-1 by calcineurin inhibition: attenuation of insulin-like growth factor-I-induced GSK-3beta and ERK pathways in adrenal chromaffin cells.
Satoh S; Yanagita T; Maruta T; Nemoto T; Yoshikawa N; Kobayashi H; Tono T; Wada A
Neuropharmacology; 2008 Jul; 55(1):71-9. PubMed ID: 18538359
[TBL] [Abstract][Full Text] [Related]
9. Development of a Novel Electrochemiluminescence ELISA for Quantification of α-Synuclein Phosphorylated at Ser
Dutta S; Hornung S; Taha HB; Biggs K; Siddique I; Chamoun LM; Shahpasand-Kroner H; Lantz C; Herrera-Vaquero M; Stefanova N; Loo JA; Bitan G
ACS Chem Neurosci; 2023 Apr; 14(7):1238-1248. PubMed ID: 36920792
[TBL] [Abstract][Full Text] [Related]
10. Leveraging Fungal and Human Calcineurin-Inhibitor Structures, Biophysical Data, and Dynamics To Design Selective and Nonimmunosuppressive FK506 Analogs.
Gobeil SM; Bobay BG; Juvvadi PR; Cole DC; Heitman J; Steinbach WJ; Venters RA; Spicer LD
mBio; 2021 Dec; 12(6):e0300021. PubMed ID: 34809463
[TBL] [Abstract][Full Text] [Related]
11. Effects of cyclosporin A, FK506 and rapamycin on calcineurin phosphatase activity in mouse brain.
Yu DY; Luo J; Bu F; Zhang W; Wei Q
IUBMB Life; 2006 Jul; 58(7):429-33. PubMed ID: 16801218
[TBL] [Abstract][Full Text] [Related]
12. A calcineurin- and NFAT-dependent pathway is involved in α-synuclein-induced degeneration of midbrain dopaminergic neurons.
Luo J; Sun L; Lin X; Liu G; Yu J; Parisiadou L; Xie C; Ding J; Cai H
Hum Mol Genet; 2014 Dec; 23(24):6567-74. PubMed ID: 25051958
[TBL] [Abstract][Full Text] [Related]
13. α-Synuclein Transgenic Drosophila As a Model of Parkinson's Disease and Related Synucleinopathies.
Mizuno H; Fujikake N; Wada K; Nagai Y
Parkinsons Dis; 2010 Dec; 2011():212706. PubMed ID: 21209707
[TBL] [Abstract][Full Text] [Related]
14. FK506 and the role of immunophilins in nerve regeneration.
Gold BG
Mol Neurobiol; 1997 Dec; 15(3):285-306. PubMed ID: 9457703
[TBL] [Abstract][Full Text] [Related]
15. FKBP12-immunopositive inclusions in patients with α-synucleinopathies.
Honjo Y; Ayaki T; Horibe T; Ito H; Takahashi R; Kawakami K
Brain Res; 2018 Feb; 1680():39-45. PubMed ID: 29246765
[TBL] [Abstract][Full Text] [Related]
16. FK506-binding protein (FKBP12) regulates ryanodine receptor-evoked Ca2+ release in colonic but not aortic smooth muscle.
MacMillan D; Currie S; McCarron JG
Cell Calcium; 2008 Jun; 43(6):539-49. PubMed ID: 17950843
[TBL] [Abstract][Full Text] [Related]
17. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
[TBL] [Abstract][Full Text] [Related]
18. The interaction between calcineurin and α-synuclein is regulated by calcium and calmodulin.
Shi X; Sun Y; Wang P; Gu L; Wang L; Yang H; Wei Q; Li Z; Luo J
Biochem Biophys Res Commun; 2018 Feb; 496(4):1109-1114. PubMed ID: 29409956
[TBL] [Abstract][Full Text] [Related]
19. Research Progress of α-Synuclein Aggregation Inhibitors for Potential Parkinson's Disease Treatment.
Kalsoom I; Wang Y; Li B; Wen H
Mini Rev Med Chem; 2023; 23(20):1959-1974. PubMed ID: 37198991
[TBL] [Abstract][Full Text] [Related]
20. α-Synuclein Induces Progressive Changes in Brain Microstructure and Sensory-Evoked Brain Function That Precedes Locomotor Decline.
Chu WT; DeSimone JC; Riffe CJ; Liu H; Chakrabarty P; Giasson BI; Vedam-Mai V; Vaillancourt DE
J Neurosci; 2020 Aug; 40(34):6649-6659. PubMed ID: 32669353
[No Abstract] [Full Text] [Related]
[Next] [New Search]
